High Tide (HITI) Acquires Queen of Bud to Expand Its Portfolio
https://www.zacks.com/stock/news/2242214/high-tide-hiti-acquires-queen-of-bud-to-expand-its-portfolio?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2242214
Mar 18, 2024 - High Tide (HITI) announces the acquisition of Queen of Bud to boost its in-house cannabis brand portfolio without burdening its significant capital expenditure.
0
Chemed (CHE) Reaches a New 52-Week High: What's Driving It?
https://www.zacks.com/stock/news/2242255/chemed-che-reaches-a-new-52-week-high-what-s-driving-it?cid=CS-ZC-FT-analyst_blog|52-week_high/low-2242255
Mar 18, 2024 - Investors are optimistic about Chemed (CHE) on strong performance across the VITAS and Roto-Rooter segments.
0
Labcorp (LH) Presents New Research on Precision Diagnostics
https://www.zacks.com/stock/news/2242254/labcorp-lh-presents-new-research-on-precision-diagnostics?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2242254
Mar 18, 2024 - Labcorp's (LH) new research shows how biomarker testing can help close testing gaps and guide tailored therapy for patients with epithelial ovarian cancer.
0
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
https://www.zacks.com/stock/news/2242241/reasons-to-retain-dexcom-dxcm-stock-in-your-portfolio-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2242241
Mar 18, 2024 - DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
0
Charles River (CRL) Extends Gene Therapy Offering With New Pact
https://www.zacks.com/stock/news/2241549/charles-river-crl-extends-gene-therapy-offering-with-new-pact?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2241549
Mar 15, 2024 - Charles River's (CRL) partnership with Navega Therapeutics will enable it to leverage its strong AAV portfolio and leading gene therapy CDMO capabilities.
0
Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now
https://www.zacks.com/stock/news/2240975/reasons-to-hold-west-pharmaceutical-wst-in-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2240975
Mar 14, 2024 - West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
0
BD's (BDX) ADC System Favored by New Study for Long-Term Care
https://www.zacks.com/stock/news/2240879/bd-s-bdx-adc-system-favored-by-new-study-for-long-term-care?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240879
Mar 14, 2024 - BD's (BDX) ADC system is likely to result in improvements in clinical workflow, operational efficiency and financial savings in long-term care facilities.
0
Inspira Technologies (IINN) Releases Favorable Data on VORTX
https://www.zacks.com/stock/news/2240756/inspira-technologies-iinn-releases-favorable-data-on-vortx?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240756
Mar 14, 2024 - Inspira Technologies' (IINN) proprietary orbiting oxygenation technology eliminates the need for membrane fibers, thereby reducing pressure differentials and high shear stress.
0
Here's Why You Should Retain Charles River (CRL) Stock Now
https://www.zacks.com/stock/news/2240683/here-s-why-you-should-retain-charles-river-crl-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2240683
Mar 14, 2024 - Investors remain optimistic about Charles River (CRL) due to the strength of the RMS segment.
0
Here's Why You Should Retain Globus Medical (GMED) Stock Now
https://www.zacks.com/stock/news/2240217/here-s-why-you-should-retain-globus-medical-gmed-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2240217
Mar 13, 2024 - Investors are optimistic about Globus Medical (GMED), led by growth in the U.S. spine business and progress in the recently merged NuVasive business.
0